DARE BIOSCIENCE INC
NASDAQ: DARE (Dare Bioscience, Inc.)
Last update: 5 hours ago0.713
-0.03 (-3.65%)
| Previous Close | 0.740 |
| Volume | 450,194 |
| Price / Earnings (Forward) | 1.27 |
| Price / Sales | 8.01 |
| Price / Book | 29.40 |
| 52 Weeks Range |
| Operating Margin (TTM) | -18,016.75% |
| Diluted EPS (TTM) | -0.170 |
| Quarterly Revenue Growth (YOY) | 173.40% |
| Total Debt/Equity (MRQ) | 218.34% |
| Current Ratio (MRQ) | 0.560 |
| Operating Cash Flow (TTM) | 6.74 M |
| Levered Free Cash Flow (TTM) | -5.85 M |
| Return on Assets (TTM) | -86.98% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Dare Bioscience, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 3.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | -0.21 |
|
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.57% |
| % Held by Institutions | 9.34% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Amh Equity Ltd | 30 Sep 2025 | 232,373 |
| Us Bancorp \De\ | 30 Jun 2026 | 120,920 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |